Study pegs certain cellular activities to driving Alzheimer’s disease. Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and progression.
The DIAN and DIAN-TU are deeply saddened by the recent death of our beloved colleague, Dr. Francisco Lopera, Principal Investigator at our site in Colombia (Grupo Neurociencias de Antioquia – GNA). Alzforum offers this remembrance, highlighting the impact of Dr. Lopera’s work on the AD field.
As discussed at the Alzheimer’s Association International Conference in Philadelphia, nearly two dozen mutation carriers who took gantenerumab for eight years had half the risk of developing symptoms as did untreated controls.
Many researchers think the full promise of plaque removal lies in prevention. If plaques were abolished before they could kick off downstream pathologies such as tangles, would the disease be stopped in its tracks?
DIAN-TU is launching the DIAN-TU-003 Amyloid Removal Trial (ART) to enable continued treatment for the DIAN-TU-001 Gantenerumab Open Label Extension (OLE) participants and address questions regarding the effects of removing amyloid plaques to normal levels on cognitive symptoms, clinical progression and disease processes.
We are now pleased to announce plans to re-launch the DIAN-TU-002 Primary Prevention Trial with remternetug in collaboration with Eli Lilly and Company (Lilly).
The soaring burden of dementia threatens global health. Science is paving new paths to solutions.
WashU School of Medicine recently dedicated the new 609,000-square-foot Jeffrey T. Fort Neuroscience Research Building, which houses some 120 research teams — one of the highest concentrations of neuroscientists in the world.
Update to the 18 August 2023 announcement by the Knight Family DIAN-TU regarding the DIAN-TU-001 Open Label Extension (OLE) Study